Skip to main content
Erschienen in: Die Onkologie 2/2020

10.11.2019 | Tumorlysesyndrom | Leitthema

Notfälle unter medikamentöser Tumortherapie

verfasst von: Dr. med. Annabel Alig, Prof. Dr. Dr. med. Michael von Bergwelt, PD Dr. med. Clemens Gießen-Jung

Erschienen in: Die Onkologie | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Onkologische Notfälle sind in der Ätiologie und Symptomatik vielfältig und treten häufig mit der Einleitung einer Chemotherapie auf, können sich aber auch während oder mit zeitlicher Verzögerung manifestieren. Die Kenntnis onkologischer Notfälle unter medikamentöser Tumortherapie ist daher nicht nur für die behandelnden Fachdisziplinen wichtig, sondern auch für mit- oder weiterbetreuende Kollegen. Jeder dieser Krankheitszustände erfordert eine sorgfältige Beurteilung der Symptome, klinische, laborchemische und apparative diagnostische Schritte sowie akute Interventionen und unterstützende Pflegemaßnahmen. Im Folgenden werden sechs häufige, akut verlaufende und/oder schwerwiegende Nebenwirkungen vorgestellt und auf das spezifische Management eingegangen.
Literatur
1.
Zurück zum Zitat Alter P, Herzum M, Soufi M et al (2006) Cardiotoxicity of 5‑fluorouracil. Cardiovasc Hematol Agents Med Chem 4:1–5 CrossRef Alter P, Herzum M, Soufi M et al (2006) Cardiotoxicity of 5‑fluorouracil. Cardiovasc Hematol Agents Med Chem 4:1–5 CrossRef
2.
Zurück zum Zitat Arriola E, Wheater M, Karydis I et al (2015) Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res 21:5642–5643 CrossRef Arriola E, Wheater M, Karydis I et al (2015) Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res 21:5642–5643 CrossRef
3.
Zurück zum Zitat Berman D, Parker SM, Siegel J et al (2010) Blockade of cytotoxic T‑lymphocyte antigen‑4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10:11 PubMedPubMedCentral Berman D, Parker SM, Siegel J et al (2010) Blockade of cytotoxic T‑lymphocyte antigen‑4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10:11 PubMedPubMedCentral
4.
Zurück zum Zitat Biffi R, Pozzi S, Agazzi A et al (2004) Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol 15:296–300 CrossRef Biffi R, Pozzi S, Agazzi A et al (2004) Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol 15:296–300 CrossRef
5.
Zurück zum Zitat Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11 CrossRef Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11 CrossRef
6.
Zurück zum Zitat Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220 CrossRef Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220 CrossRef
7.
Zurück zum Zitat Cassagnol M, Mcbride A (2009) Management of chemotherapy extravasations. US Pharm 34(9):3–11 Cassagnol M, Mcbride A (2009) Management of chemotherapy extravasations. US Pharm 34(9):3–11
8.
Zurück zum Zitat Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27:559–574 CrossRef Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27:559–574 CrossRef
9.
Zurück zum Zitat Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778 CrossRef Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778 CrossRef
10.
Zurück zum Zitat Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 28:4207–4213 CrossRef Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 28:4207–4213 CrossRef
11.
Zurück zum Zitat De Forni M, Malet-Martino MC, Jaillais P et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801 CrossRef De Forni M, Malet-Martino MC, Jaillais P et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801 CrossRef
13.
Zurück zum Zitat Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346–1353 CrossRef Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346–1353 CrossRef
14.
Zurück zum Zitat Gomes ER, Demoly P (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5:309–316 CrossRef Gomes ER, Demoly P (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5:309–316 CrossRef
15.
Zurück zum Zitat Gupta A, De Felice KM, Loftus EV Jr. et al (2015) Systematic review: colitis associated with anti-CTLA‑4 therapy. Aliment Pharmacol Ther 42:406–417 CrossRef Gupta A, De Felice KM, Loftus EV Jr. et al (2015) Systematic review: colitis associated with anti-CTLA‑4 therapy. Aliment Pharmacol Ther 42:406–417 CrossRef
16.
Zurück zum Zitat Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142 CrossRef Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142 CrossRef
17.
Zurück zum Zitat Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50 CrossRef Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50 CrossRef
18.
Zurück zum Zitat Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364:1844–1854 CrossRef Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364:1844–1854 CrossRef
19.
Zurück zum Zitat Howard SC, Trifilio S, Gregory TK et al (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95:563–573 CrossRef Howard SC, Trifilio S, Gregory TK et al (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95:563–573 CrossRef
20.
Zurück zum Zitat Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5‑fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–493 CrossRef Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5‑fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–493 CrossRef
21.
Zurück zum Zitat Jones GL, Will A, Jackson GH et al (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661–671 CrossRef Jones GL, Will A, Jackson GH et al (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661–671 CrossRef
22.
Zurück zum Zitat Jones RL, Swanton C, Ewer MS (2006) Anthracycline cardiotoxicity. Expert Opin Drug Saf 5:791–809 CrossRef Jones RL, Swanton C, Ewer MS (2006) Anthracycline cardiotoxicity. Expert Opin Drug Saf 5:791–809 CrossRef
23.
Zurück zum Zitat Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079–1095 CrossRef Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079–1095 CrossRef
24.
Zurück zum Zitat Langer SW, Sehested M, Jensen PB (2009) Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori 95:273–282 CrossRef Langer SW, Sehested M, Jensen PB (2009) Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori 95:273–282 CrossRef
25.
Zurück zum Zitat Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601–609 CrossRef Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601–609 CrossRef
26.
Zurück zum Zitat Ma WW, Saif MW, El-Rayes BF et al (2017) Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5‑fluorouracil and capecitabine toxicity. Cancer 123:345–356 CrossRef Ma WW, Saif MW, El-Rayes BF et al (2017) Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5‑fluorouracil and capecitabine toxicity. Cancer 123:345–356 CrossRef
27.
Zurück zum Zitat Marthey L, Mateus C, Mussini C et al (2016) Cancer immunotherapy with anti-CTLA‑4 Monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10:395–401 CrossRef Marthey L, Mateus C, Mussini C et al (2016) Cancer immunotherapy with anti-CTLA‑4 Monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10:395–401 CrossRef
28.
Zurück zum Zitat Mercuro G, Cadeddu C, Piras A et al (2007) Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12:1124–1133 CrossRef Mercuro G, Cadeddu C, Piras A et al (2007) Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12:1124–1133 CrossRef
29.
Zurück zum Zitat Miller KK, Gorcey L, Mclellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787–794 CrossRef Miller KK, Gorcey L, Mclellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787–794 CrossRef
30.
Zurück zum Zitat Mouridsen HT, Langer SW, Buter J et al (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18:546–550 CrossRef Mouridsen HT, Langer SW, Buter J et al (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18:546–550 CrossRef
31.
Zurück zum Zitat Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD‑1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391 CrossRef Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD‑1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391 CrossRef
32.
Zurück zum Zitat Perez Fidalgo JA, Garcia Fabregat L, Cervantes A et al (2012) Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol 23(Suppl 7):vii167–vii173 CrossRef Perez Fidalgo JA, Garcia Fabregat L, Cervantes A et al (2012) Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol 23(Suppl 7):vii167–vii173 CrossRef
33.
Zurück zum Zitat Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 71:203.e1–203.12 (quiz 215–206) CrossRef Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 71:203.e1–203.12 (quiz 215–206) CrossRef
34.
Zurück zum Zitat Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532 CrossRef Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532 CrossRef
35.
Zurück zum Zitat Rosen AC, Balagula Y, Raisch DW et al (2014) Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 25:225–234 CrossRef Rosen AC, Balagula Y, Raisch DW et al (2014) Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 25:225–234 CrossRef
37.
Zurück zum Zitat Schimmel KJ, Richel DJ, Van Den Brink RB et al (2004) Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–191 CrossRef Schimmel KJ, Richel DJ, Van Den Brink RB et al (2004) Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–191 CrossRef
38.
Zurück zum Zitat Sudhoff T, Enderle MD, Pahlke M et al (2004) 5‑Fluorouracil induces arterial vasocontractions. Ann Oncol 15:661–664 CrossRef Sudhoff T, Enderle MD, Pahlke M et al (2004) 5‑Fluorouracil induces arterial vasocontractions. Ann Oncol 15:661–664 CrossRef
39.
Zurück zum Zitat Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728 CrossRef Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728 CrossRef
40.
Zurück zum Zitat Wengstrom Y, Margulies A (2008) European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs 12:357–361 CrossRef Wengstrom Y, Margulies A (2008) European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs 12:357–361 CrossRef
41.
Zurück zum Zitat Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD‑1 therapy. Eur J Cancer 60:210–225 CrossRef Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD‑1 therapy. Eur J Cancer 60:210–225 CrossRef
Metadaten
Titel
Notfälle unter medikamentöser Tumortherapie
verfasst von
Dr. med. Annabel Alig
Prof. Dr. Dr. med. Michael von Bergwelt
PD Dr. med. Clemens Gießen-Jung
Publikationsdatum
10.11.2019
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 2/2020
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-019-00672-x

Weitere Artikel der Ausgabe 2/2020

Die Onkologie 2/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.